Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Ascites Market

ID: MRFR/HC/54586-HCR
200 Pages
Satyendra Maurya
Last Updated: March 28, 2026

UK Ascites Market Research Report: By Type (Transudative Ascites, Exudate Ascites), By Diagnosis (Ultrasound, CT Scan, Laparoscopy, Angiography), By Treatment (Surgeries) andBy End User (Hospitals & Clinics, Ambulatory Surgical Center, Diagnostic Centers)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 UK Ascites Market, BY Application (USD Million)
      1. 4.1.1 Diagnostic
      2. 4.1.2 Therapeutic
      3. 4.1.3 Prognostic
      4. 4.1.4 Research
    2. 4.2 UK Ascites Market, BY Type of Ascites (USD Million)
      1. 4.2.1 Malignant Ascites
      2. 4.2.2 Non-Malignant Ascites
      3. 4.2.3 Transudative Ascites
      4. 4.2.4 Exudative Ascites
    3. 4.3 UK Ascites Market, BY Treatment Method (USD Million)
      1. 4.3.1 Paracentesis
      2. 4.3.2 Diuretics
      3. 4.3.3 Surgical Intervention
      4. 4.3.4 Transjugular Intrahepatic Portosystemic Shunt
    4. 4.4 UK Ascites Market, BY Patient Demographics (USD Million)
      1. 4.4.1 Age Group
      2. 4.4.2 Gender
      3. 4.4.3 Underlying Conditions
      4. 4.4.4 Socioeconomic Status
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the UK Ascites Market
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the UK Ascites Market
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Gilead Sciences (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co. (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AbbVie (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Pfizer (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY APPLICATION
    3. 6.3 UK MARKET ANALYSIS BY TYPE OF ASCITES
    4. 6.4 UK MARKET ANALYSIS BY TREATMENT METHOD
    5. 6.5 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 KEY BUYING CRITERIA OF UK ASCITES MARKET
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF UK ASCITES MARKET
    9. 6.9 DRIVERS IMPACT ANALYSIS: UK ASCITES MARKET
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: UK ASCITES MARKET
    11. 6.11 SUPPLY / VALUE CHAIN: UK ASCITES MARKET
    12. 6.12 UK ASCITES MARKET, BY APPLICATION, 2024 (% SHARE)
    13. 6.13 UK ASCITES MARKET, BY APPLICATION, 2024 TO 2035 (USD Million)
    14. 6.14 UK ASCITES MARKET, BY TYPE OF ASCITES, 2024 (% SHARE)
    15. 6.15 UK ASCITES MARKET, BY TYPE OF ASCITES, 2024 TO 2035 (USD Million)
    16. 6.16 UK ASCITES MARKET, BY TREATMENT METHOD, 2024 (% SHARE)
    17. 6.17 UK ASCITES MARKET, BY TREATMENT METHOD, 2024 TO 2035 (USD Million)
    18. 6.18 UK ASCITES MARKET, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    19. 6.19 UK ASCITES MARKET, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY TYPE OF ASCITES, 2026-2035 (USD Million)
      3. 7.2.3 BY TREATMENT METHOD, 2026-2035 (USD Million)
      4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Ascites Market Segmentation

UK Ascites Market By Application (USD Million, 2022-2035)

  • Diagnostic
  • Therapeutic
  • Prognostic
  • Research

UK Ascites Market By Type of Ascites (USD Million, 2022-2035)

  • Malignant Ascites
  • Non-Malignant Ascites
  • Transudative Ascites
  • Exudative Ascites

UK Ascites Market By Treatment Method (USD Million, 2022-2035)

  • Paracentesis
  • Diuretics
  • Surgical Intervention
  • Transjugular Intrahepatic Portosystemic Shunt

UK Ascites Market By Patient Demographics (USD Million, 2022-2035)

  • Age Group
  • Gender
  • Underlying Conditions
  • Socioeconomic Status

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions